Últimas investigaciones científicas sobre cáncer colorrectal
Copia esta URL y pégala en tu lector RSS favorito (Feedly, Inoreader, etc.)
https://crcwarriors.org/api/scientific-news.php?action=rss
Drug-eluting bead transarterial chemoembolisation (DEB-TACE), particularly irinotecan-based regimens, has emerged as a liver-directed option for unresectable colorectal liver metastases (CRLM), yet how metastatic-niche biology relates to local drug delivery remains poorly defined. We integrated bulk...
Lynch syndrome (LS) is a common hereditary cancer syndrome caused by pathogenic germline variants in one of the DNA mismatch repair genes. In the past few decades, advances in understanding the molecular basis of LS and LS-related tumorigenesis have led to the development and ongoing refinement of L...
Selenium-binding protein 1 (SELENBP1) correlates positively with the prognosis of patients with colitis and colon cancer. SELENBP1-deficient dendritic cells (DCs) promote regulatory T cell differentiation and exert direct immunomodulatory functions. This study aimed to investigate whether SELENBP1-d...
Liquid biopsy guided anti-EGFR rechallenge therapy is gaining ground as a potential option for patient with refractory metastatic colorectal cancer. However, the identification of potential biomarkers to implement patient's stratification is required. The CAVE-2 GOIM trial investigated the role of r...
Gastrointestinal neuroendocrine carcinomas (GI-NECs) are aggressive tumors with marked site-specific heterogeneity, yet molecular markers for colorectal origin are lacking. This study characterized genomic and protein expression profiles to identify origin-specific biomarkers. Nineteen GI-NECs (7 es...
Methods: To assess the impact of TBX1 on the proliferation and colony-forming capacity of colorectal cancer cells, in vitro functional investigations were carried out. Concurrently, a subcutaneous xenograft mouse model was established to determine the influence of TBX1 on tumor growth in vivo. Throu...
Synthetic biology has redefined the therapeutic role of microbes, transforming them from passive commensals or delivery vehicles into programmable living therapeutics capable of sensing, computing, and actuating within host tissues. This transformation is particularly relevant to metabolic disorders...
Colorectal cancer remains a leading cause of global cancer mortality, with a concerning rise in early-onset cases driven by complex interactions between environmental exposures, lifestyle factors, and host genetics. Mounting evidence indicates that gut microbiota dysbiosis critically modulates this ...
Gastrointestinal (GI) cancers, including colorectal, gastric, pancreatic, hepatocellular, and esophageal malignancies, remain a leading cause of cancer-related mortality worldwide. Emerging evidence identifies the gut microbiome as a critical regulator of GI carcinogenesis, influencing tumor initiat...
Obesity is one of the primary risk factors for colorectal cancer (CRC) development, but the impact of obesity on therapeutic responses to anti-programmed cell death protein 1 (PD-1) immunotherapy in CRC remains unclear. This retrospective study investigates relationships between body mass index (B...
Second-line treatment for metastatic colorectal cancer (mCRC) typically involves oxaliplatin- or irinotecan-based doublet chemotherapy with or without anti-angiogenic antibodies. Triplet regimens such as FOLFOXIRI have demonstrated synergy and improved efficacy as first-line therapy. Surufatinib, an...
The rapid development of therapies linked to molecular biomarkers has increased the importance of next-generation sequencing (NGS)-based tumor profiling to guide treatment decisions. Technology has enabled more comprehensive clinical testing; however, the optimal economic approach deserves investiga...
Focused ultrasound, low-intensity focused ultrasound, and microbubble-enhanced sonoporation are examples of ultrasound-based cancer therapies that have shown promise as biophysical modalities for enhancing drug penetration, immunogenic cell death, and targeted delivery of radiopharmaceuticals in sol...
Early-stage gastroesophageal junction cancer (GEJC) and low rectal cancer (LRC) pose a dilemma: surgery is often curative yet may cause lasting functional loss. Emerging data suggest that early tumors tend to exhibit an immune-active microenvironment with greater tertiary lymphoid structures (TLS) d...
KRAS-G12D mutations are common drivers of pancreatic and colorectal cancers, yet effective targeted therapies remain limited. This study describes the design, synthesis, and biological evaluation of two novel KRAS-G12D inhibitors, GD-2 and GD-4. Both compounds exhibited strong antiproliferative acti...
To assess the survival benefit of synchronous systemic therapy plus thermal ablation (TA) in oligometastatic colorectal lung metastases (CRLM) and identify independent prognostic factors. Optimizing the integration of systemic therapy and TA for potentially curable CRLM remains a significant clinica...
Glatiramer acetate (GA) is a heterogeneous mixture of peptides that we have previously explored as an intratumoral immunomodulator. However, its chemical complexity complicates the mechanistic interpretation and rational design. In this study, we evaluated a set of sequence-defined "glatiramoid" pep...
Precise and non-invasive cancer diagnosis remains a persistent pursuit for clinicians. DNA circuit, owing to its biocompatibility and capability for complex information processing, has been explored for cancer diagnostics. Here, we established a cancer diagnosis platform based on a novel DNA weighte...
Short-chain fatty acids (SCFAs) mediate host-microbiota interactions and are typically measured in feces as markers of gut microbial activity. However, whether fecal SCFAs adequately reflect disease-associated host-microbiota dysfunction remains unclear. We hypothesized that circulating SCFAs, which...
Colorectal cancer (CRC) screening is crucial for early detection, yet the invasiveness of the gold-standard colonoscopy limits compliance. To address the limitation, this study proposes a novel multi-target free DNA methylation model and evaluated its risk stratification performance for CRC in high-...
Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide, and the liver is its predominant site of metastatic spread; approximately half of patients with CRC develop colorectal liver metastases (CRLM). Management has shifted from largely palliative intent t...
Covalent KRASG12C inhibitors have changed the treatment landscape for patients with non-small cell lung cancer and colorectal cancer, but numerous RAS-mutant cancers lack approved targeted therapies. In this study, we describe RMC-8839, an oral RAS(ON) G13C-selective, covalent, tricomplex inhibitor ...
Objective: To construct and validate an overall survival (OS) prediction model for patients with colorectal cancer liver metastases (CRLM) undergoing R0 resection after conversion therapy. Methods: A total of 364 patients with CRLM who were evaluated by a multidisciplinary team as initially unresect...
PD-(L)1×VEGF bispecific antibodies integrate immune checkpoint blockade and VEGF inhibition within a single molecule, offering a potential strategy to overcome angiogenesis-associated immune resistance. At the 2026 ASCO Annual Meeting, the randomized phase 3 HARMONi-6 trial demonstrated an overall ...
Liposomal irinotecan, characterized by its favorable pharmacologic properties and reduced systemic toxicity compared to irinotecan, has demonstrated superior therapeutic potential. This multicenter, single-arm study was conducted to evaluate the efficacy and safety of liposomal irinotecan, capecitab...
This study aimed to synthesize evidence from recent randomized controlled trials (RCTs) evaluating the efficacy of regorafenib, fruquintinib, and TAS-102 in patients with metastatic colorectal cancer (mCRC). Using a network meta-analysis, we compared long-term survival outcomes (overall and progress...
Microsatellite-stable colorectal cancer (MSS-CRC) remains broadly refractory to immune checkpoint blockade, underscoring the need for strategies that convert immunologically "cold" tumors into therapy-responsive states. Here, we identify 4-hydroxyphenylpyruvate dioxygenase (HPD), the rate-limiting e...
Chemoresistance, often driven by aberrant transcriptional and epigenetic mechanisms, remains a significant barrier to effective colon cancer therapy. This study introduces a dendrimer-based proteolysis-targeting chimera (PROTAC) system, JTP, generated by conjugation of polyamidoamine (PAMAM-G4) dend...
BRAF V600E-mutant metastatic colorectal cancer (mCRC) represents an aggressive molecular subtype associated with poor prognosis and limited response to conventional chemotherapy. Although multiple targeted strategies, including anti-vascular endothelial growth factor (VEGF), anti-epidermal growth fa...
Gastrointestinal malignancies remain leading causes of cancer mortality, yet their sensitivity to immunotherapy differs sharply across anatomical sites, histologies, molecular subtypes, and disease stages. Immune checkpoint blockade has established durable clinical benefit in microsatellite instabil...
Colorectal cancer (CRC) treatment is severely hindered by the hydrogen sulfide (H2S)-rich microenvironment and metabolic dysregulation, characterized by the Warburg effect and high glutathione (GSH) concentrations. Herein, we engineer a bimetallic phenolic nanoplatform (ZCTDFe, loaded with doxorubic...
Conventional surgery for locally advanced rectal cancer (LARC) faces challenges including difficult sphincter preservation and high recurrence rates. Neoadjuvant immunotherapy holds promise for addressing this clinical challenge by reducing the preoperative tumor burden and activating immune memory....
Inefficient clearance of tumor-associated cellular debris sustains chronic inflammation and reinforces tumor-promoting immune niches in the colorectal cancer (CRC), yet strategies to selectively enhance macrophage-mediated cellular debris clearance remain largely unexplored. Here, we engineered a du...
Neoadjuvant immune checkpoint blockade induces high pathological response rates in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer, yet long-term survival outcomes have not been established. Previously, we reported safety (a primary endpoint) and pathological response (a...
Colorectal cancer (CRC) exhibits substantial molecular heterogeneity, requiring integrative approaches to define clinically meaningful tumour subtypes. Although large international consortia have extensively profiled CRC, global datasets underrepresent many ethnicities. Understanding how local tumor...
The role of a comprehensive genomic profile (CGP) and molecular residual disease (MRD) in circulating tumor DNA (ctDNA) for risk stratification of resectable colorectal oligometastases (CRMs) remains unclear. This study aimed to investigate the feasibility of ctDNA analysis in patients with CRM and ...
Chimeric antigen receptor (CAR) T cell therapy is considered a therapeutic breakthrough in hematological malignancies. However, its translation to metastasized solid tumors remains limited by the paucity of "druggable" targets and the limited therapeutic potency of the cell therapeutics in solid can...
Background: Pathological complete response (pCR) after neoadjuvant immunotherapy is associated with improved prognosis in colon and rectal cancer. This study aimed to develop and validate a predictive nomogram for pCR in CRC patients receiving neoadjuvant immunotherapy. Methods: A total of 232 eligi...
Over the past decade, targeting Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations has shifted from being considered an undruggable target to becoming a realistic therapeutic strategy with the development of KRASG12C inhibitors. This mutation replaces glycine with cysteine at codon 12, ther...
Background/Objectives: Colon interposition, or esophagocoloplasty, remains an important reconstructive option when the native esophagus cannot be preserved or when the stomach is unsuitable for reconstruction. Malignant transformation within the interposed colon is rare but clinically relevant, beca...
Immune checkpoint inhibitors (ICIs) have transformed the management of mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC), yet the ~95% of patients with mismatch repair-proficient/microsatellite-stable (pMMR/MSS) disease derive little benefit owing to an i...
T cells recognize tumor-specific neoantigens presented by human leukocyte antigen (HLA) molecules and can mediate potent antitumor immunity. However, most neoantigens are patient-specific, limiting their broad therapeutic applicability. KRAS G12V is a recurrent oncogenic mutation found in multiple c...
Telisotuzumab adizutecan (ABBV-400, Temab-A) is an antibody-drug conjugate targeting c-Met (MET) protein with adizutecan, a novel topoisomerase 1 inhibitor payload. In monotherapy dose escalation, Temab-A demonstrated a manageable safety profile and promising antitumor activity in advanced colorecta...
Rising incidence of colorectal cancer (CRC) and limited therapeutic options highlight the urgent need to define the drivers of its progression. The SPP1+ tumor-associated macrophage (TAM) subset identified by single-cell transcriptomics is a functionally dominant population that extends beyond the c...
Epithelial-mesenchymal transition (EMT) is involved in colorectal cancer (CRC) pathogenesis. Curcumin (CUR) is widely used in the treatment of CRC. Polystyrene nanoparticles (PS-NPS) have a high specific affinity and have an inhibitory effect on cell proliferation. Therefore, the purpose of this stu...
Colorectal cancer (CRC) continues to be a major contributor to cancer-related mortality, with advancements in immunotherapy progress impeded by suboptimal patient responses. Immunogenic cell death (ICD), a distinct process that promotes antitumor immunity, has garnered significant attention in oncol...
The phase III CheckMate 8HW trial met its dual primary endpoints of superior progression-free survival (PFS) with nivolumab plus ipilimumab (NIVO + IPI) versus chemotherapy [first-line (1L)] and versus NIVO (all lines) in patients with centrally confirmed microsatellite instability-high (MSI-H)/mism...
Multimodal treatment with chemotherapy, radiation, and surgery for locally advanced rectal cancer (LARC) is a standard of care (SOC) associated with significant toxicity/morbidity. After TNT, clinical complete response (cCR) ranges between 21-41%, highlighting the need for novel approaches. dMMR/MSI...
Later-line treatment for metastatic colorectal cancer (mCRC) has shifted from purely pursuing survival prolongation to a chronic disease management model that balances survival with quality of life (QoL). Conventional line-by-line drug sequencing faces efficacy plateaus and tolerability challenges, ...
KRAS gene mutations represent one of the most common drivers of human cancers, with particularly high prevalence in pancreatic, lung, and colorectal cancers. Among these, the KRASG12D mutation has long been considered an "undruggable" target because of its unique structural characteristics. This art...